[
  {
    "ts": null,
    "headline": "5 Insightful Analyst Questions From Revvity’s Q1 Earnings Call",
    "summary": "Revvity delivered a first quarter that reflected solid execution amid a volatile macroeconomic backdrop, with sales outpacing Wall Street expectations and organic growth supported by resilient diagnostics and software segments. Management cited stabilized demand from pharmaceutical and biotech customers and a notable rebound in diagnostics, especially in areas like newborn screening. CEO Prahlad Singh pointed to unexpected softness in U.S. academic spending, which affected life science instrumen",
    "url": "https://finnhub.io/api/news?id=057eb5082c9122cf97a72cb2b1fe208c13c0b61311274d1432b7ea2ea94aa0a5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751282446,
      "headline": "5 Insightful Analyst Questions From Revvity’s Q1 Earnings Call",
      "id": 135672404,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "RVTY",
      "source": "Yahoo",
      "summary": "Revvity delivered a first quarter that reflected solid execution amid a volatile macroeconomic backdrop, with sales outpacing Wall Street expectations and organic growth supported by resilient diagnostics and software segments. Management cited stabilized demand from pharmaceutical and biotech customers and a notable rebound in diagnostics, especially in areas like newborn screening. CEO Prahlad Singh pointed to unexpected softness in U.S. academic spending, which affected life science instrumen",
      "url": "https://finnhub.io/api/news?id=057eb5082c9122cf97a72cb2b1fe208c13c0b61311274d1432b7ea2ea94aa0a5"
    }
  }
]